Search the Newsreel

RGNX|Regenxbio Inc|Price:10.180|Chg%:+0.060

The article provides a comprehensive stock analysis of Regenxbio Inc (RGNX) from TradingKey, highlighting its relatively weak fundamentals but significant growth potential. The stock is considered fairly valued, with high institutional ownership and multiple "Buy" ratings from analysts. The company, a clinical-stage biotechnology firm, …

XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of XBiotech Inc (XBIT), detailing its current price momentum score, support and resistance levels, and indicator readings. It also includes an overview of various technical indicators like MACD, RSI, and moving averages, offering insights into potential trading signals. …

Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO) as of July 30, 2026. The company currently holds a valuation score of 8.31, ranking 140 out of 384 in its industry, with a P/E ratio of -2.14. The article notes that relevant …

XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for XBiotech Inc (XBIT), noting its current valuation score of 7.74, ranking 184th in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.70, contrasting it with recent highs and lows. The analysis …

REGENXBIO (RGNX) Projected to Post Earnings on Thursday

Xenetic Biosciences Inc (XBIO) Institutional Confidence

Xenetic Biosciences Inc (XBIO) currently holds an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 53.00% quarter-over-quarter, now standing at 4.97%. James Simons is identified as the …

Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Xenetic Biosciences Inc (XBIO), highlighting its current risk score of 1.12, which ranks 326 out of 385 in the Biotechnology & Medical Research industry. It details the company's beta value of 2.12, indicating higher volatility compared to …

Xenetic Biosciences, Inc. Revenue Breakdown – MUN:3XB0

This article provides a revenue breakdown for Xenetic Biosciences, Inc. (MUN:3XB0), highlighting the United States as its primary revenue source. In the last year, the U.S. contributed €2.53 million, closely following €2.42 million from the previous year. The information is presented within the context …

Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis

Xenetic Biosciences Inc (XBIO) has a strong financial health score of 8.45, ranking 44th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 36.01% to $806.92K and a net profit increase of 49.47%. Despite its robust financial …

XBIT|XBiotech Inc|Price:2.280|Chg%:+0.020

This article provides a comprehensive stock analysis of XBiotech Inc (XBIT) by TradingKey. It highlights the company's strong fundamentals and significant growth potential, although its stock price is expected to trend down in the medium term. The analysis also covers XBiotech's business in developing …

XBiotech Inc (XBIT) Income Statement

This article provides the quarterly and annual income statements for XBiotech Inc (XBIT), detailing various financial metrics such as revenue, operating expenses, net income, and earnings per share. It also includes frequently asked questions about how to interpret these financial statements and key metrics …

Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0

The article provides a financial snapshot of REGENXBIO, Inc. (HAM:RB0) on TradingView, specifically focusing on its diluted shares outstanding. It notes that the market for HAM:RB0 is currently closed with no trades recorded. The content seems to be a financial data placeholder, indicating where …

Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Xenetic Biosciences Inc (XBIO). It indicates that the company has not distributed any dividends in the past five years. However, it lists a 10-to-1 merger-related stock split event that occurred on May …

XBiotech Inc (XBIT) Institutional Confidence

XBiotech Inc (XBIT) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.25%, marking a 42.58% increase quarter-over-quarter. James Simons is the largest institutional shareholder with 0.07% …

Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Regenxbio Inc's (RGNX) dividend and stock split history, indicating that no dividends have been distributed over the past five years. It presents current stock performance data, including its market cap and recent price change. The page is part …

Inventory turnover of REGENXBIO, Inc. – HAM:RB0

This article focuses on the inventory turnover of REGENXBIO, Inc. (HAM:RB0). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred. The content suggests the financial data provided is made by humans and …

XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for XBiotech Inc (XBIT). It indicates that XBiotech Inc has distributed a total of $0.00 in dividends over the past five years and currently has no dividend data available. The page also shows the current stock …

XBiotech Inc (XBIT) Cash Flow

This article provides a comprehensive quarterly and annual cash flow statement for XBiotech Inc (XBIT), detailing operating, investing, and financing activities from FY2013Q4 to FY2026Q1. It includes specific figures for net income, operating gains/losses, changes in working capital, capital expenditures, and free cash flow. …

XBiotech Inc (XBIT) Balance Sheet

This article presents the detailed balance sheet data for XBiotech Inc (XBIT) on a quarterly and annual basis, spanning several years. It includes key financial metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity, allowing investors to assess the company's …

XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of XBiotech Inc (XBIT), listing its major individual shareholders and institutional holdings. It provides a breakdown of shareholder types by proportion and outlines institutional shareholding trends over several quarters. Additionally, it highlights activities of key shareholders and lists …

Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Xenetic Biosciences Inc (XBIO), noting that relevant data regarding business segments, regional revenue, and profit contribution has not been disclosed by the company. It highlights the current stock price, market capitalization, and indicates a lack of detailed …

XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for XBiotech Inc (XBIT). It notes that relevant data regarding business segments, regional revenue, and profit contribution has not been disclosed by the company yet, with 0.00% of revenue coming from the United States. The article …

XBIO|Xenetic Biosciences Inc|Price:2.550|

Xenetic Biosciences Inc. (XBIO) is a biopharmaceutical company focused on immuno-oncology technologies, specifically advancing its Deoxyribonuclease (DNase) technology to treat difficult cancers. The company's DNase technology targets neutrophil extracellular traps (NETs) to improve existing cancer treatments, including immunotherapies. XBIO is developing this technology for …

Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Xenetic Biosciences Inc (XBIO), identifying major individual and institutional holders. It provides a breakdown of shareholder types, including hedge funds, corporations, and individual investors, and lists institutional shareholding changes over several quarters. Key investors like Renaissance Technologies …

TradingKey

This article provides a detailed quarterly and annual income statement for Xenetic Biosciences Inc (XBIO) through FY2026Q1, emphasizing key financial metrics like total revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret these financial statements on the …

Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Regenxbio Inc (RGNX), detailing its price momentum score, current trading range, and a summary of technical indicators and moving averages. RGNX currently has a price momentum score of 5.89 and is trading between a resistance level of …

XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085

Xenetic Biosciences Inc. (XBIO) shows "relatively very healthy" fundamentals and high growth potential, though its valuation is considered "fairly valued" within the Biotechnology & Medical Research industry. The company, focused on immuno-oncology technologies, has seen steady revenue growth and holds significant institutional ownership. Despite …

REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX

The article provides a revenue breakdown for REGENXBIO Inc. (NASDAQ: RGNX), highlighting that the company generated $170.44 million USD last year. Its top-performing segment was Gene Therapies, contributing the entire $170.44 million, an increase from $83.33 million the previous year. Japan was the largest …

REGENXBIO Inc. (RGNX) stock price, news, quote and history

This article provides comprehensive financial data for REGENXBIO Inc. (RGNX), including its stock price, historical performance, earnings, and analyst insights. As of July 24, 2026, RGNX closed at $9.73, down 5.07%, with an after-hours price of $9.79. The company, a clinical-stage biotechnology firm, specializes …

Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.

Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on Phase I/II study …

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 trial study, specifically concerning its efficacy and …

Frontier tech research, news & data

This article reports on an 8-K filing by REGENXBIO Inc. on July 20, 2026, detailing other events. It also highlights a research report on fuel-cell deployments at U.S. data centers, indicating 154 MW of operating capacity and 6.31 GW in proposed projects across various …

Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD

Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare sura-vec against …

REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M

REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriters' 30-day option for …

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safety through five years for wet AMD patients …

REGENXBIO Stock Slides After $100M Equity Offering Shock

REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating alleged misleading statements about …